{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:08:33Z","timestamp":1779314913452,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We herein compare topical interferon alpha 2b (IFN-\u03b12b) to topical mitomycin C (MMC) in the adjuvant management after excision of primary acquired melanosis with atypia (PAM) and melanoma of the conjunctiva\/cornea (CM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 25 tumors from 25 patients (six with PAM and 19 with CM). After surgical excision, four patients started with adjuvant IFN-\u03b12b (two in combination with radiotherapy), 19 with MMC, and two with radiotherapy alone. Five patients were switched from initial MMC\/radiotherapy to IFN-\u03b12b during follow-up. Efficacy was assessed via time to tumor recurrence and initial therapy response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>With initial IFN-\u03b12b, three patients (3\/4, two with additional radiotherapy) showed complete remission (follow-up: 1478\u20131750\u00a0days) and one recurrence (1\/4) was noted after 492\u00a0days. With initial MMC, no recurrence was recorded in 15 of the 19 patients (follow-up: 99\u20134732\u00a0days). Five patients were switched from MMC or radiotherapy to IFN-\u03b12b: two patients showed complete remission (2\/5), while another two (2\/5) experienced recurrences and remained without recurrence after repeated courses of IFN-\u03b12b (follow-up: 1798 and 1973\u00a0days). Only one patient showed incomplete response. Adverse effects were recorded in five patients, all received MMC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Topical IFN-\u03b12b (arguably together with radiotherapy) may be a viable alternative to MMC in PAM and CM. We observed fewer side effects at similar response rates. However, when response to MMC was poor, IFN-\u03b12b may also be of limited utility.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-022-05832-1","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T10:02:51Z","timestamp":1666087371000},"page":"1159-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-life data of adjuvant IFN-\u03b12b and MMC in conjunctival melanocytic lesions"],"prefix":"10.1007","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-8344","authenticated-orcid":false,"given":"Simone","family":"Nuessle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Auw-Haedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Boehringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"5832_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","volume":"93","author":"E Triay","year":"2009","unstructured":"Triay E, Bergman L, Nilsson B et al (2009) Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol 93:1524\u20131528. https:\/\/doi.org\/10.1136\/bjo.2009.157933","journal-title":"Br J Ophthalmol"},{"key":"5832_CR2","doi-asserted-by":"publisher","unstructured":"Jain P, Finger PT, Fili M, et al (2020) Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. Br J Ophthalmol bjophthalmol 2020\u2013316293. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316293","DOI":"10.1136\/bjophthalmol-2020-316293"},{"issue":"389\u2013395","key":"5832_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ophtha.2010.06.021","volume":"118","author":"CL Shields","year":"2011","unstructured":"Shields CL, Markowitz JS, Belinsky I et al (2011) Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 118(389\u2013395):e1-2. https:\/\/doi.org\/10.1016\/j.ophtha.2010.06.021","journal-title":"Ophthalmology"},{"key":"5832_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s0161-6420(02)00967-3","volume":"109","author":"S Tuomaala","year":"2002","unstructured":"Tuomaala S, Aine E, Saari KM, Kivel\u00e4 T (2002) Corneally displaced malignant conjunctival melanomas. Ophthalmology 109:914\u2013919. https:\/\/doi.org\/10.1016\/s0161-6420(02)00967-3","journal-title":"Ophthalmology"},{"key":"5832_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.4103\/ijo.IJO_2040_19","volume":"67","author":"CL Shields","year":"2019","unstructured":"Shields CL, Shields JA (2019) Tumors of the conjunctiva and cornea. Indian J Ophthalmol 67:1930\u20131948. https:\/\/doi.org\/10.4103\/ijo.IJO_2040_19","journal-title":"Indian J Ophthalmol"},{"key":"5832_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ajo.2020.10.020","volume":"223","author":"T Milman","year":"2021","unstructured":"Milman T, Eiger-Moscovich M, Henry RK et al (2021) Validation of the newly proposed World Health Organization classification system for conjunctival melanocytic intraepithelial lesions: a comparison with the C-MIN and PAM classification schemes. Am J Ophthalmol 223:60\u201374. https:\/\/doi.org\/10.1016\/j.ajo.2020.10.020","journal-title":"Am J Ophthalmol"},{"key":"5832_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40123-019-00219-8","volume":"8","author":"VML Cohen","year":"2019","unstructured":"Cohen VML, O\u2019Day RF (2019) Management issues in conjunctival tumours: conjunctival melanoma and primary acquired melanosis. Ophthalmol Ther 8:501\u2013510. https:\/\/doi.org\/10.1007\/s40123-019-00219-8","journal-title":"Ophthalmol Ther"},{"key":"5832_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/bjo.77.11.751","volume":"77","author":"PT Finger","year":"1993","unstructured":"Finger PT, Milner MS, McCormick SA (1993) Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol 77:751\u2013753","journal-title":"Br J Ophthalmol"},{"key":"5832_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s00417-004-1080-y","volume":"243","author":"M Kurli","year":"2005","unstructured":"Kurli M, Finger PT (2005) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years\u2019 experience. Graefe\u2019s Arch Clin Exp Ophthalmo 243:1108\u20131114. https:\/\/doi.org\/10.1007\/s00417-004-1080-y","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmo"},{"key":"5832_CR10","first-page":"449","volume":"39","author":"JG Crowston","year":"1998","unstructured":"Crowston JG, Akbar AN, Constable PH et al (1998) Antimetabolite-induced apoptosis in Tenon\u2019s capsule fibroblasts. Invest Ophthalmol Vis Sci 39:449\u2013454","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5832_CR11","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.ophtha.2011.01.060","volume":"118","author":"LC Ditta","year":"2011","unstructured":"Ditta LC, Shildkrot Y, Wilson MW (2011) Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology 118:1754\u20131759. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.060","journal-title":"Ophthalmology"},{"key":"5832_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s00347-004-1149-3","volume":"102","author":"N Feltgen","year":"2005","unstructured":"Feltgen N, Auw-H\u00e4drich C (2005) Exceptional conjunctival tumor in a young allergic woman. Ophthalmologe 102:1204\u20131206. https:\/\/doi.org\/10.1007\/s00347-004-1149-3","journal-title":"Ophthalmologe"},{"key":"5832_CR13","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","volume":"117","author":"CL Karp","year":"2010","unstructured":"Karp CL, Galor A, Chhabra S et al (2010) Subconjunctival\/perilesional recombinant interferon \u03b12b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology 117:2241\u20132246. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.052","journal-title":"Ophthalmology"},{"key":"5832_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s1359-6101(01)00022-3","volume":"13","author":"F Belardelli","year":"2002","unstructured":"Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119\u2013134. https:\/\/doi.org\/10.1016\/s1359-6101(01)00022-3","journal-title":"Cytokine Growth Factor Rev"},{"key":"5832_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ajo.2007.08.027","volume":"145","author":"PT Finger","year":"2008","unstructured":"Finger PT, Sedeek RW, Chin KJ (2008) Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol 145:124\u2013129. https:\/\/doi.org\/10.1016\/j.ajo.2007.08.027","journal-title":"Am J Ophthalmol"},{"key":"5832_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00417-009-1189-0","volume":"248","author":"TR Herold","year":"2010","unstructured":"Herold TR, Hintschich C (2010) Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 248:111\u2013115. https:\/\/doi.org\/10.1007\/s00417-009-1189-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5832_CR17","first-page":"1043","volume":"115","author":"S Kase","year":"2011","unstructured":"Kase S, Ishijima K, Noda M, Ishida S (2011) Two cases of conjunctival malignant melanoma treated with topical interferon alpha-2b drop as an adjuvant therapy. Nippon Ganka Gakkai Zasshi 115:1043\u20131047","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"5832_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00347-012-2736-3","volume":"110","author":"C Schumacher","year":"2013","unstructured":"Schumacher C, Heinz C, Lommatzsch P et al (2013) Interferon alpha 2b for treatment of conjunctival melanoma: a case report. Ophthalmologe 110:766\u2013769. https:\/\/doi.org\/10.1007\/s00347-012-2736-3","journal-title":"Ophthalmologe"},{"key":"5832_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/2008-322X.156127","volume":"10","author":"F Ghassemi","year":"2015","unstructured":"Ghassemi F, Ghadimi H, Nikdel M (2015) Resolution of primary acquired melanosis with atypia after treatment with topical mitomycin C and interferon alfa-2b. J Ophthalmic Vis Res 10:84\u201386. https:\/\/doi.org\/10.4103\/2008-322X.156127","journal-title":"J Ophthalmic Vis Res"},{"key":"5832_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/01676830.2015.1093509","volume":"35","author":"A Garip","year":"2016","unstructured":"Garip A, Schaumberger MM, Wolf A et al (2016) Evaluation of a short-term topical interferon \u03b1-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia. Orbit 35:29\u201334. https:\/\/doi.org\/10.3109\/01676830.2015.1093509","journal-title":"Orbit"},{"key":"5832_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3109\/09273948.2015.1115880","volume":"25","author":"V Huerva","year":"2017","unstructured":"Huerva V, Traveset AE, Vilardell F (2017) Topical interferon alpha-2b for diffuse conjunctival primary acquired melanosis with atypia. Ocul Immunol Inflamm 25:284\u2013286. https:\/\/doi.org\/10.3109\/09273948.2015.1115880","journal-title":"Ocul Immunol Inflamm"},{"key":"5832_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00417-017-3754-2","volume":"255","author":"I Kikuchi","year":"2017","unstructured":"Kikuchi I, Kase S, Ishijima K, Ishida S (2017) Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection. Graefes Arch Clin Exp Ophthalmol 255:2271\u20132276. https:\/\/doi.org\/10.1007\/s00417-017-3754-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5832_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.oftal.2018.06.008","volume":"93","author":"TA Chaparro Tapias","year":"2018","unstructured":"Chaparro Tapias TA, D\u00edaz D\u00edaz AL, Secondi R et al (2018) Resolution of conjunctival melanoma with topical interferon alpha 2b in a patient with mitomycin C intolerance. Arch Soc Esp Oftalmol 93:558\u2013561. https:\/\/doi.org\/10.1016\/j.oftal.2018.06.008","journal-title":"Arch Soc Esp Oftalmol"},{"key":"5832_CR24","doi-asserted-by":"publisher","first-page":"100467","DOI":"10.1016\/j.ajoc.2019.100467","volume":"15","author":"MJ Benage","year":"2019","unstructured":"Benage MJ, Morrow NC, Janson BJ, Greiner MA (2019) Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma. Am J Ophthalmol Case Rep 15:100467. https:\/\/doi.org\/10.1016\/j.ajoc.2019.100467","journal-title":"Am J Ophthalmol Case Rep"},{"key":"5832_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ophtha.2009.07.032","volume":"117","author":"A Lichtinger","year":"2010","unstructured":"Lichtinger A, Pe\u2019er J, Frucht-Pery J, Solomon A (2010) Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. Ophthalmol 117:431\u2013437. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.032","journal-title":"Ophthalmol"},{"key":"5832_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/08820530500351694","volume":"21","author":"AM Poothullil","year":"2006","unstructured":"Poothullil AM, Colby KA (2006) Topical medical therapies for ocular surface tumors. Semin Ophthalmol 21:161\u2013169. https:\/\/doi.org\/10.1080\/08820530500351694","journal-title":"Semin Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05832-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T07:06:33Z","timestamp":1679987193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5832"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05832-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"20 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the ethics committee of the Albert-Ludwig University Freiburg, Germany (74\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}